Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.
The 2024 ECTRIMS meeting, which took place September 18-20 in Copenhagen, Denmark, featured significant updates in multiple sclerosis (MS) and related disorders, including neuromyelitis optica spectrum disorder (NMOSD). Key themes included cutting-edge research, antibody-mediated mimics of MS, development of biomarkers, and personalized therapies. There were also important discussions on managing NMOSD and other neuroinflammatory conditions, emphasizing new treatment strategies and clinical trial results, as well as the comparative effectiveness of available disease-modifying therapies.
Joseph R. Berger, MD
Professor, Department of Neurology, Perelman School of Medicine; Associate Director, Department of Neurology, Multiple Sclerosis Division, University of Pennsylvania, Philadelphia, Pennsylvania
"I would argue, given the fact that these drugs not only appear to be substantially more effective but quite safe, that we should be adopting high-efficacy therapy with these newer FDA-approved drugs for NMOSD as first-line therapy for the condition."
Preconference Considerations
ECTRIMS 2024: Anticipating New Treatment Strategies and Biomarkers in NMOSD
Dr Berger is eager to see expanded discussions on optimal treatment strategies for neuromyelitis optica spectrum disorders at the upcoming ECTRIMS 2024 meeting, including head-to-head comparisons of newer drugs and their real-world experiences. He is also interested in advancements in biomarker research for monitoring disease activity and treatment efficacy, as well as insights into antibody-negative cases and their underlying mechanisms. Additionally, understanding the connection between these disorders and co-existing conditions like lupus would be valuable for improving treatment and prevention strategies.
Quick Clinical Takeaways
ECTRIMS 2024: New Biomarkers and Real-World Data on Treatments for NMOSD
Dr Berger relates how key presentations at ECTRIMS 2024 highlighted advancements in treating NMOSD, including a study from China identifying four predictive biomarkers. A standout presentation from Harvard researchers reviewed treatment outcomes in 107 patients, revealing high failure rates for older therapies rituximab and azathioprine, while newer treatments such as satralizumab and eculizumab showed significantly lower relapse rates and hospitalization.
How Will My Patients Benefit?
ECTRIMS 2024: New Insights on Understanding and Treating NMOSD
Dr Berger reviews new findings on neuromyelitis optica spectrum disorders (NMOSD) presented at the recent ECTRIMS conference, particularly its pathogenesis regarding B-cell involvement and the role of the IL-6 receptor. The effectiveness and safety of newer FDA-approved treatments, such as satralizumab and inebilizumab, which outperformed traditional therapies like mycophenolate mofetil and rituximab, are also underscored and supported by a Harvard study indicating that these newer agents not only improve patient outcomes but also result in fewer hospitalizations, suggesting they should be prioritized as first-line treatments for NMOSD.
Polling Question
Summary
At ECTRIMS 2024, recent findings shed light on the evolving understanding of neuromyelitis optica spectrum disorders (NMOSD), particularly regarding the role of B cells and the IL-6 receptor in disease progression. Other data announced a significant shift from older treatment approaches, as newer FDA-approved therapies like satralizumab and inebilizumab demonstrate enhanced efficacy and safety profiles. A compelling study from Harvard underscored the substantial benefits of these treatments, showing improved patient outcomes and reduced hospitalization rates compared with traditional options. Reflecting on this progress, Dr Berger concludes that it becomes clear that adopting these advanced therapies as first-line treatments could greatly reduce the morbidity associated with NMOSD.
Resources:
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Conference MDAngle: ECTRIMS 2024 Neuromyelitis Optica Spectrum Disorder - Medscape - Sep 09, 2024.
Comments